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INTRODUCTION
Current indications for left ventricular assist device (LVAD) 
implantation include either chronic or acute heart failure (HF) 
in patients who cannot be stabilised with medical therapy and 
in whom the maintenance of sufficient end-organ perfusion 
is impossible. Based on international data, LVADs are now 
being used for months to years in patients who either face 
a long-term wait on the transplant list or who are not eligible 
for transplantation as a destination therapy [1]. Furthermore, 
by 2015, device implantation strategy has become a destina-
tion therapy in nearly 50% of implants [2].
Nevertheless, several challenges remain to be overcome 
before LVADs will be considered as the therapy of choice for all 
patients with advanced HF, because one-year survival free of 
any major adverse events remains at only 30% [3, 4]. Although 
thrombotic events are not the most frequent complication, 
they can contribute significantly to patient mortality [5–7]. 
Suspected pump thrombosis (PT) is an event in which 
clinical or mechanical circulatory support device parameters 
suggest thrombus in the blood contacting components of the 
pump, cannulae, or grafts. Signs and symptoms should include 
at least two of the three following criteria: haemolysis, wors-
ening HF, and abnormal pump parameters (elevated pump 
powers > 10 W or 2 W higher than baseline) [8]. 
Available methods of treatment involve one or more of 
the following interventions: treatment with intravenous anti-
coagulation (e.g. unfractionated heparin [UFH]), intravenous 
thrombolytics (e.g. tissue plasminogen activator [tPA]), or 
intravenous antiplatelet therapy (e.g. eptifibatide, tirofiban); 
pump replacement; pump explantation or urgent transplanta-
tion (United Network for Organ Sharing [UNOS] status 1A) [8]. 
Our Institution has experience with over 30 implants 
since October 2015 with both Heartmate III (Thoratec Cor-
poration, Pleasanton, CA, USA) and HeartWare (Medtronic, 
Framingham, MA, USA) LVADs. In the study we present an 
innovative algorithm of rescue treatment for acute PT in pa-
tients with high risk of bleeding complications. 
METHODS
The study is a retrospective analysis of medical records of three 
consecutive patients who underwent LVAD implantation in 
the Department of Cardiovascular Surgery and Transplantol-
ogy, John Paul II Hospital, Krakow (Table 1). Following the 
implantation protocol, in all of the cases antithrombotic man-
agement within early postoperative days was obtained with 
intravenously administered UFH guided by activated partial 
thromboplastin time (up to 50 s within the first 48 h and 75 s 
in later postoperative days). After chest tube removal, warfarin 
was introduced with a target international normalised ratio 
(INR) of 3.0 to 3.5. On postoperative day 1 lavage function 
was enabled, following the manufacturer’s recommendation, 
to diminish the risk of a potential thrombotic event. 
RESULTS AND DISCUSSION
All patients received IV UFH bolus as soon as the PT diagnosis 
was established; however, no response to the treatment was 
observed. On the contrary, constant increase in LVAD power 
consumption was noted. All patients were considered to be 
at high risk of bleeding complications, with contraindications 
to standard thrombolytic approach. Moreover, our Institution 
does not have experience with emergent pump exchange. 
Facing the need for a rescue strategy, we elaborated an in-
www.kardiologiapolska.pl
Rescue treatment for LVAD thrombosis
1111
novative algorithm of thrombolytic treatment guided by the 
LVAD power consumption and flow curves. 
The UFH drip was discontinued and instant thrombolytic 
treatment was started. Thrombolysis was achieved with in-
travenous recombinant tPA, Actylise® (Boehringer Ingelheim, 
Ingelheim am Rhein, Germany) drip (50 mg/50 mL; starting 
flow 30 mL/h), which resulted in quick but stepwise drop in 
LVAD power consumption. The therapy was maintained until 
initial LVAD parameters were achieved, which was dynami-
cally observed and analysed on the power consumption and 
flow curves. The drip flow was reduced gradually every 10 to 
15 min, until complete withdrawal. 
In two patients PT reoccurred within the same hospi-
talisation, and thrombolytic treatment was implemented 
successfully once and twice again following the same protocol 
(patients G.P. and P.M., respectively). 
Currently, within a median follow-up of nine months since 
the thrombotic event (P.M. — 14 months, G.P. — nine months, 
K.M. — four months) all patients remain well, presenting New 
York Heart Association class I. After the PT event psychological 
consultation and further education were applied, and warfarin 
was implemented again as the anticoagulation therapy of choice, 
with good compliance. Patients are routinely monitored, and 
regular control of log-files and lactate dehydrogenase levels 
confirms proper LVAD functioning with no thrombotic events.
Despite steady improvement in survival since the im-
plementation of the new-era continuous-flow pumps, the 
prevalence of PT with the HeartMate II and HeartWare 
LVADs is reported with a rate of 0.08 per patient/year [7, 9]. 
Although the aetiology and contribution of platelet- and 
thrombin-dependent pathways for thrombus formation in 
LVAD patients remain unclear [6], in the presented analysis all 
patients experienced a thrombotic event due to unsatisfactory 
outcomes of antithrombotic management. In two cases (G.P., 
K.M.), warfarin was discontinued and patients were bridged 
with therapeutic dose of subcutaneous low-molecular-weight 
heparin (LMWH) due to alcohol abuse undiagnosed prior to 
implantation. In both individuals with pathological INR reach-
ing up to 11.0, severe and recurrent haemoglobin drops due 
to gastrointestinal bleedings were observed during warfarin 
administration. The third patient (P.M.) received antibiotics 
(rifampicin orally) due to a drive-line infection. The patient 
was bridged with LMWH due to a potential drug interaction; 
however, he continued taking warfarin orally despite pre-
scribed treatment for about five days and did not take LMWH. 
The optimal strategy of treatment for various groups of 
patients experiencing PT remains unresolved. Based on the 
literature, strong conclusions should be drawn with caution, 
because the data are limited mostly to case reports, case 
series, or small, single-institution cohorts with a great variety 
Table 1. Patients’ characteristics
Variable Patient P.M. Patient G.P. Patient K.M.
Age [years] 45 51 54
Sex Male Male Male
CAD Yes Yes No
Atrial fibrillation Persistent Paroxysmal Paroxysmal
ICD Yes Yes Yes
Cardiomyopathy Dilated Dilated Dilated
LVAD HVAD HVAD HVAD
Time to PT [months] 4.5 13 20
Antithrombotic treatment on admission Warfarin* LMWH LMWH
Antiplatelet treatment on admission ASA ASA ASA
Primary reason for not taking VKA – Severe GI bleeding, unstable INR  
due to alcohol abuse
Severe GI  
bleeding
Time from onset of LMWH treatment to PT [months] –** 6 10.5
LVAD power consumption at the onset of IV tPA treatment [W] 21 14 6:61
Maximum observed LDH level before onset of IV tPA treatment [U/L] 11,592 9654 1753
*Patient received antibiotics (rifampicin orally) due to a drive-line infection, bridged with LMWH but continued taking warfarin against prescribed 
treatment
**According to the patient warfarin was taken instead of LMWH for few days, probably 5
ASA — acetylsalicylic acid; CAD — coronary artery disease; GI — gastrointestinal; HVAD — HeartWare ventricular assist device; ICD — implantable 
cardioverter-defibrillator; INR — international normalised ratio; LDH — lactate dehydrogenase; LMWH — low-molecular-weight heparin;  
LVAD — left ventricular assist device; PT — pump thrombosis; tPA — tissue plasminogen activator; VKA — vitamin K antagonists
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of treatment strategies, drug choices, and delivery methods 
[5, 6, 9–11]. 
This proposed innovative algorithm of thrombolytic 
treatment guided by the power consumption and flow curves 
was elaborated while facing dramatic LVAD dysfunction and 
emergent need of rescue strategy in patients with high risk of 
bleeding complications. tPA was chosen as the safest avail-
able thrombolytic agent [12] and due to the algorithm, it was 
administered in the smallest effective dose. 
The use of the log-system to predict the success of tPA 
treatment was first described in 2015 [10, 13]. Neverthe-
less, our report is the first to describe the usefulness of the 
real-time power and flow characteristic analysis to guide 
the thrombolytic therapy in patients with PT, which allows 
patient-tailored dosing because it is based on constant moni-
toring of effectiveness.
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